Current Report Filing (8-k)
June 14 2019 - 4:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
|
June
14, 2019
|
|
PROTAGENIC
THERAPEUTICS, INC.
(Exact
name of Company as specified in its charter)
Delaware
|
|
000-51353
|
|
06-1390025
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
149
Fifth Avenue, Suite 500, New York, NY
|
|
10010
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
212-994-8200
(Company’s telephone number, including area code)
(Former name or former address, if changed
since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01 Other Events
2019
Annual Meeting of Stockholders; Date for Submission of Stockholder Proposals
Protagenic
Therapeutics, Inc. (the “Company”) currently intends to hold its annual meeting of stockholders on Monday, September
23, 2019 (the “2019 Annual Meeting”). The exact time of the 2019 Annual Meeting, which will be a “virtual”
annual meeting, will be specified in the Company’s proxy statement for the 2019 Annual Meeting.
Because
the expected date of the 2019 Annual Meeting represents a change of more than 30 calendar days from the date of the anniversary
of the Company’s 2018 annual meeting of stockholders, the Company is affirming the deadline for receipt of stockholder proposals
submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for inclusion
in the Company’s proxy materials for the 2019 Annual Meeting. In order to be considered timely, such proposals must be received
in writing by the Company’s Corporate Secretary at the Company’s principal executive offices at 149 Fifth Avenue,
Suite 500, New York, NY 10010 by the close of business on Monday, July 15, 2019 (which the Company has determined to be a reasonable
time before it expects to begin to print and send its proxy materials). Such proposals also must comply with the applicable requirements
of Rule 14A-8 of the Exchange Act regarding the inclusion of stockholder proposals in company-sponsored proxy materials and other
applicable laws.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
PROTAGENIC
THERAPEUTICS, INC.
|
|
|
|
Date:
June 14, 2019
|
By:
|
/s/
Alexander K. Arrow
|
|
Name:
|
Alexander
K. Arrow
|
|
Title:
|
Chief
Financial Officer
|